Breaking News, Collaborations & Alliances

TRACON and Ambrx Enter Development Agreement

The partnership resolves around the commercialization and development of TRC105 (carotuximab) in China

TRACON Pharmaceuticals has entered into a licensing agreement with Ambrx for the development and commercialization of TRACON’s proprietary endoglin antibody, TRC105 (carotuximab), in China.   The transaction grants Ambrx the exclusive rights to develop and commercialize TRC105 in all indications in China and Taiwan. TRACON will receive an upfront payment of $3 million, and is eligible to receive development and regulatory milestones of up to $10.5 million, and commercial sales milestones...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters